Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 847

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 847
---
 Balance at end of period           |     | $                        | 250 |     | $    | 241 |

F-112

KINETA, INC. Notes to Consolidated Financial Statements 4. Balance Sheet Components Property and Equipment, Net There was no property and equipment as of December 31, 2024 or December 31, 2023. Depreciation and amortization expense was zero for the year ended December 31, 2024 and $9,000 for the year ended December 31, 2023. The Company did not dispose of any assets during the year ended December 31, 2024. During the year ended December 31, 2023, the Company disposed of assets with a net carrying value of $240,000 and received proceeds of $331,000. The Company recorded a gain on disposal of fixed assets, which is recorded in other income (expense) in the Statement of Operations. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of the periods presented:

|                                                      |     | December 31,   
 2024           
 (in thousands) |       |     | 2023 |       |
|:-----------------------------------------------------|:----|:---------------|------:|:----|:-----|------:|
| Compensation and benefits                            |     | $              |   696 |     | $    | 1,312 |
| Professional services                                |     |                | 1,238 |     |      |    97 |
| Accrued interest                                     |     |                |   228 |     |      |   417 |
| Accrued clinical trial and preclinical costs         |     |                |    80 |     |      |   251 |
| Other                                                |     |                |   119 |     |      |   134 |
| Total accrued expenses and other current liabilities |     | $              | 2,361 |     | $    | 2,211 |

| 5. | Notes Payable |

Notes payable outstanding consisted of the following as of the periods presented:

|                                       |     | December 31, 2024 |     |     |            |     |     | December 31, 2023 |     |     |            |     |
|:--------------------------------------|:----|:------------------|----:|:----|:-----------|----:|:----|:------------------|----